Fmr US Navy SEAL George Hodgin On Producing Federally-Compliant Cannabis-Based Medical Products

Fmr US Navy SEAL George Hodgin On Producing Federally-Compliant Cannabis-Based Medical Products

George Hodgin, CEO of BRC and former US Navy SEAL: “We’ve been working really hard to get prepared for this stage of BRC, when we could partner with innovative pharmaceutical companies and research institutions, like CURE, in compliance with federal law.”

See the source image

“Our goal with this partnership is to bring tangible, federally legal cannabis treatments to a wide variety of patients using cannabis from our operation.”

Cannabis that is of a higher quality than had been previously been available to researchers and pharmaceutical companies. We’ve been building this company because we know that cannabis has significant potential as a way to treat myriad health conditions. Working with CURE is a dream come true, and we can’t wait to start developing game-changing treatments together.”

This is our first cannabis cultivation partnership since becoming licensed by the DEA.  BRC will supply the ingredients and CURE will contribute its formulation development, regulatory, and commercial manufacturing capability, as well as support clinical studies.”

“The partnership will initiate the development of CBD and Tetrahydrocannabinol (THC) oral thin films for CURE’s clinical studies targeted at advancing veteran’s health and other important public health conditions.​

“Both of these companies will do so in compliance with federal law.”

DEA-Licensed Biopharmaceutical Research Company to Partner with CURE Pharmaceutical to Produce Federally-Compliant Cannabis-Based Medical Products

The joint agreement is for the production of cannabis-based finished products inclusive of active raw material and supply from BRC for use in CURE’s formulation development, regulatory, and commercial manufacturing capability, as well as support of clinical studies. 

The partnership will initiate the development of CBD and THC oral thin films for CURE’s clinical studies targeted at advancing veteran health. 

“Off the heels of receiving our DEA license, the partnership we’ve undertaken with CURE is an exciting inaugural project for deploying our cannabis cultivation technology,” said BRC CEO George Hodgin. “CURE has established itself as a leader in the oral application of cannabis-derived treatments, and we know we’ll be able to bring a lot of value to patients together.” 

BRC was recently awarded one of the only federal production licenses from the DEA to produce clean, consistent and compliant cannabis for federally approved researchers across the United States. 

“Our company, which also has a Schedule 1 DEA license, is committed to federal compliance when it comes to the development of our products, making BRC a perfect partner for this project,” said Rob Davidson, CURE Pharmaceutical CEO. “We’ve been working to develop safe, accurately-dosed cannabis solutions for several years now and we believe that this collaboration will help us take that initiative to the next level and expand our capacities.” 

CURE currently produces multiple commercial CBD oral film products in compliance with the 2018 U.S.Farm Bill and European regulations. Its patent-pending products are shelf-stable,bioavailable, and feature multiple taste-masking and flavor solutions. 

About Biopharmaceutical Research Company

BRC is a specialty pharmaceutical company that holds several DEA Registrations and is pioneering the federally legal cannabis space in the USA. BRC also conducts federally compliant cannabis-specific analytical activities. 

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

Fmr US Navy SEAL George Hodgin On Producing Federally-Compliant Cannabis-Based Medical Products

Becoming a Navy SEAL